Resources Repository
-
ArticlePublication 2022Comparative Health Systems Analysis of Differences in Catastrophic Health Expenditure
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications …
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). This article compares non-communicable diseases catastrophic health expenditure to the CHE cases caused by communicable diseases across health systems to examine whether: (1) disease burden and catastrophic health expenditure are linked, (2) Catastrophic health expenditures secondary to NCDs disproportionately affect wealthier households and (3) whether the drivers…
Evidence Synthesis | Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Costing Methods | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2022Comparing Health Gains, Costs & Cost-Effectiveness of Interventions in Australia & New Zealand
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New …
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New Zealand (NZ) from studies conducted with comparable methods, and reports results in the form of an online interactive league table. Studies from the Australia Cost-Effectiveness research and NZ Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programmes and studies were included which reported health-adjusted life years (HALYs) and net health system costs and/or incremental cost-effectiveness ratios, used a time horizon of…
Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Priority Setting/Ethics | Chronic Disease/Risk | Mental Health | Health/Medicine | Asia & Pacific | Oceania -
ArticlePublication 2021Health Opportunity Cost Threshold for CEA in the U.S.
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, …
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, the authors simulated the short-term mortality and morbidity resulting from increased premium related cancelation of insurance coverage. The authors used this model to estimate cost-effectiveness thresholds, in dollars per quality-adjusted life year (QALY) gained based on health opportunity costs. They reported the number of persons who dropped insurance coverage, resulting number of additional deaths and QALYs lost from mortality and…
Evidence Synthesis | Cost-Effectiveness Analysis | Health Systems | Priority Setting/Ethics | Health Outcomes | Microsimulation | Policy/Regulation | Health/Medicine | North America -
ArticlePublication 2020Economic Evaluation of HBV Birth Dose Vaccination
This article, published in Cost Effectiveness and Resource Allocation, examines the cost-effectiveness of a birth …
This article, published in Cost Effectiveness and Resource Allocation, examines the cost-effectiveness of a birth dose of HBV vaccine in a medical setting in Ethiopia. The authors construct a decision analytic model with a Markov process to estimate the costs and effects of a birth dose of HBV vaccine, compared with current practices in Ethiopia. Based on the cost-effectiveness findings, introducing a birth dose of HBV vaccine in Ethiopia would likely be highly cost-effective. Such…
Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2020Financial Burden of HIV and TB
This article, published in BMJ Open, aims to estimate the household economic burden and incidence …
This article, published in BMJ Open, aims to estimate the household economic burden and incidence of catastrophic health expenditures (CHE) incurred as a result of HIV and TB care across income quintiles in Ethiopia. The economic burden of HIV and TB care is estimated looking at direct and indirect costs, whereas the incidence of CHE is determined using direct costs that exceed 10% of the household income threshold. HIV and TB are found to cause…
Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2020Health Gains & Financial Risk Protection Afforded by Public Financing of Selected Malaria Interventions in Ethiopia: An ECEA
This article, published in the Malaria Journal, aims to estimate the expected health and financial …
This article, published in the Malaria Journal, aims to estimate the expected health and financial risk protection (FRP) benefits of universal public financing of key malaria interventions in Ethiopia. An extended cost-effectiveness analysis (ECEA) is used to estimate the potential health and FRP benefits of publicly financing a 10% increase in artemisinin-based combination therapy (ACT), long-lasting insecticide-treated bed nets (LLIN), indoor residual spraying (IRS), and a hypothetical malaria vaccine. The results indicate that ACT, LLIN,…
Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Priority Setting/Ethics | Social Determinants | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2019Health and Financial Benefits of Averting Malaria in Zambia: An ECEA
This study used the extended cost-effectiveness analysis (ECEA) to examine impact of the hypothetical rollout …
This study used the extended cost-effectiveness analysis (ECEA) to examine impact of the hypothetical rollout of the malaria vaccine RTS,S/AS01 in Zambia on the health benefits of children under five, and financial benefits on their households. The authors assumed a three-dose vaccination schedule (over 6-9 months), and vaccine cost of US$5 per dose. To assess vaccine impact, for each income quintile, they computed the number of under-five malaria deaths prevented, the household out-of-pocket (OOP) malaria-related…
Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Priority Setting/Ethics | Mathematical Models | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2019Systematic Review of Economic Evaluations of Vaccination Strategies Against Tuberculosis
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited …
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited and varies by age, so a valid cost-effectiveness study is needed to assist decision-makers in the implementation of cost-effective strategies for BCG vaccination. Using the Quality of Health Economic Studies (QHES) instrument, the authors assessed the quality of published studies involving economic evaluations of BCG vaccination strategies in a variety of regions, target populations, and vaccine types. Most of the…
Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Mathematical Models | Health/Medicine | Global -
ArticleWeb Portal 2017PLoS Collection: Prevention, Diagnosis and Treatment of Sexually Transmitted Infections
Globally, the World Health Organization (WHO) estimates that more than one million new sexually transmitted …
Globally, the World Health Organization (WHO) estimates that more than one million new sexually transmitted infections (STIs) occur each day, incurring a very substantial burden of morbidity, mortality and additional infections. The pathogens responsible include bacteria, parasites and viruses, and intensive research is needed to address the substantial barriers to diagnosis and treatment of STIs, and the behavioral challenges of prevention. This PLOS collection, published in collaboration with WHO, focuses on global policy and systems…
Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Mathematical Models | Dynamic Transmission | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific